Enfortumab Vedotin – Mechanism, Uses & Side Effects
Enfortumab vedotin is an antibody-drug conjugate used to treat advanced urothelial carcinoma. It combines a targeted antibody with a potent chemotherapy agent.
Things worth knowing about "Enfortumab"
Enfortumab vedotin is an antibody-drug conjugate used to treat advanced urothelial carcinoma. It combines a targeted antibody with a potent chemotherapy agent.
What is Enfortumab Vedotin?
Enfortumab vedotin (brand name: Padcev) is an antibody-drug conjugate (ADC) – a class of targeted cancer therapy. It is used in the treatment of urothelial carcinoma, a type of cancer that arises from the lining of the urinary tract, most commonly the bladder. The drug was developed by Astellas Pharma and Seagen and is approved in both the United States and the European Union.
Indication
Enfortumab vedotin is indicated for adult patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-based chemotherapy and a PD-1 or PD-L1 checkpoint inhibitor. In combination with the immunotherapy drug pembrolizumab, it is also approved as a first-line treatment for certain patients who are not eligible for platinum-based chemotherapy.
Mechanism of Action
Enfortumab vedotin consists of three key components:
- Enfortumab: A monoclonal antibody that specifically targets the protein Nectin-4, which is highly overexpressed on the surface of most urothelial cancer cells.
- Linker: A chemical bridge that connects the antibody to the cytotoxic drug and allows selective release inside tumor cells.
- MMAE (Monomethylauristatin E): A potent chemotherapy agent and microtubule inhibitor that is released inside the cancer cell, blocking cell division and triggering cell death (apoptosis).
This targeted delivery mechanism concentrates the chemotherapy within tumor cells while largely sparing healthy tissue.
Dosage and Administration
Enfortumab vedotin is administered as an intravenous (IV) infusion, typically in an outpatient or inpatient oncology setting. The standard dose is 1.25 mg per kilogram of body weight, given on days 1, 8, and 15 of a 28-day treatment cycle. The treating oncologist may adjust the dose based on individual tolerability and side effects.
Side Effects
Like all cancer therapies, enfortumab vedotin can cause side effects. The most commonly reported include:
- Peripheral neuropathy (tingling, numbness, or pain in the hands and feet)
- Fatigue and general weakness
- Hair loss (alopecia)
- Skin reactions, including dry skin and rash
- Nausea and decreased appetite
- Elevated blood sugar levels (hyperglycemia)
- Eye irritation or excessive tearing (epiphora)
Serious but less common side effects include severe skin reactions (such as Stevens-Johnson syndrome), pneumonitis (lung inflammation), and elevated liver enzymes. Patients should report any new or worsening symptoms to their healthcare provider promptly.
Clinical Significance
Urothelial carcinoma is among the most prevalent urinary tract cancers worldwide. In advanced stages, treatment options have historically been limited, particularly for patients who progress after standard chemotherapy. Enfortumab vedotin represents a significant therapeutic advance. In the pivotal EV-301 clinical trial, it demonstrated a statistically significant improvement in overall survival compared to standard chemotherapy. When combined with pembrolizumab in the EV-302 trial, the regimen showed even greater efficacy, establishing a new standard of care for first-line treatment in eligible patients.
References
- European Medicines Agency (EMA): Padcev (Enfortumab Vedotin) – Summary of Product Characteristics and Assessment Report. https://www.ema.europa.eu (accessed 2024)
- Powles T. et al. – Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine, 2024; 390(10):875-888.
- Rosenberg JE et al. – EV-301 Study: Enfortumab Vedotin versus Chemotherapy in Platinum-Treated Advanced Urothelial Carcinoma. Journal of Clinical Oncology, 2021; 39(22):2399-2411.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryLenvatinib
Butyric acid
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Enfortumab